Yoon et al. underlined that EPHB6 mutation induces cell adhesion-mediated paclitaxel resistance via EPHA2 and CDH11 expression in LC and proposed ALW-II-41-27 therapy to suppress EPHB6 (Q926R)-induced CDH11 expression and focal adhesion formation [74]. Here, EPHA2 is linked to laryngotracheoesophageal cleft.